{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:25:57Z","timestamp":1792571157688,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018262","name":"Intercept Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018262","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cld.2025.09.003","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T01:37:04Z","timestamp":1761356224000},"page":"167-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic and Alcohol-Associated"],"prefix":"10.1016","volume":"30","author":[{"given":"Rahul","family":"Sandella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Rinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cld.2025.09.003_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.cld.2025.09.003_bib2","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2025.09.003_bib3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study","volume":"9","author":"Israelsen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.09.003_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/apt.18015","article-title":"Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality","volume":"60","author":"Tamaki","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.cld.2025.09.003_bib7","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/add.14234","article-title":"Global statistics on alcohol, tobacco and illicit drug use: 2017 status report","volume":"113","author":"Peacock","year":"2018","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.cld.2025.09.003_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.6185","article-title":"Association between daily alcohol intake and risk of all-cause mortality: a systematic review and meta-analyses","volume":"6","author":"Zhao","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10152","key":"10.1016\/j.cld.2025.09.003_bib9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cld.2025.09.003_bib10","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.3390\/ijms22105170","article-title":"Alcohol-related liver disease: basic mechanisms and clinical perspectives","volume":"22","author":"Liu","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cld.2025.09.003_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2296-6-17","article-title":"Frequency of alcohol use and obesity in community medicine patients","volume":"6","author":"Rohrer","year":"2005","journal-title":"BMC Fam Pract"},{"issue":"32","key":"10.1016\/j.cld.2025.09.003_bib12","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.3748\/wjg.v16.i32.4055","article-title":"Relationship between alcohol intake and dietary pattern: findings from NHANES III","volume":"16","author":"Liangpunsakul","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2025.09.003_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s13679-014-0129-4","article-title":"Alcohol consumption and obesity: an update","volume":"4","author":"Traversy","year":"2015","journal-title":"Curr Obes Rep"},{"issue":"12","key":"10.1016\/j.cld.2025.09.003_bib14","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/sj.ijo.0803034","article-title":"Alcohol and adiposity: effects of quantity and type of drink and time relation with meals","volume":"29","author":"Wannamethee","year":"2005","journal-title":"Int J Obes"},{"issue":"2","key":"10.1016\/j.cld.2025.09.003_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40520-013-0026-9","article-title":"Alcohol consumption and body composition in a population-based sample of elderly Australian men","volume":"25","author":"Coulson","year":"2013","journal-title":"Aging Clin Exp Res"},{"issue":"3","key":"10.1016\/j.cld.2025.09.003_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1079\/PHN2004680","article-title":"Alcohol intake in relation to body mass index and waist-to-hip ratio: the importance of type of alcoholic beverage","volume":"8","author":"Lukasiewicz","year":"2005","journal-title":"Public Health Nutr"},{"key":"10.1016\/j.cld.2025.09.003_bib17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1471-2458-5-126","article-title":"Patterns of alcohol drinking and its association with obesity: data from the third national health and nutrition examination survey, 1988-1994","volume":"5","author":"Arif","year":"2005","journal-title":"BMC Public Health"},{"issue":"8","key":"10.1016\/j.cld.2025.09.003_bib18","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1161\/HYPERTENSIONAHA.124.22703","article-title":"Alcohol intake and risk of hypertension: a systematic review and dose-response meta-analysis of nonexperimental cohort studies","volume":"81","author":"Cecchini","year":"2024","journal-title":"Hypertension"},{"issue":"26","key":"10.1016\/j.cld.2025.09.003_bib19","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199506293322601","article-title":"Suppression of alcohol-induced hypertension by dexamethasone","volume":"332","author":"Randin","year":"1995","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.cld.2025.09.003_bib20","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1530-0277.2008.00781.x","article-title":"Expression of renin-angiotensin system and peroxisome proliferator-activated receptors in alcoholic cardiomyopathy","volume":"32","author":"Jing","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"issue":"10","key":"10.1016\/j.cld.2025.09.003_bib21","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.3390\/nu13103419","article-title":"Alcohol's impact on the cardiovascular system","volume":"13","author":"Roerecke","year":"2021","journal-title":"Nutrients"},{"issue":"22","key":"10.1016\/j.cld.2025.09.003_bib22","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/archinte.166.22.2437","article-title":"Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies","volume":"166","author":"Di Castelnuovo","year":"2006","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.cld.2025.09.003_bib23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pcad.2018.02.001","article-title":"Alcohol and CV health: jekyll and hyde J-curves","volume":"61","author":"O'Keefe","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"issue":"13","key":"10.1016\/j.cld.2025.09.003_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008202","article-title":"Sex-specific associations between alcohol consumption and incidence of hypertension: a systematic review and meta-analysis of cohort studies","volume":"7","author":"Roerecke","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.cld.2025.09.003_bib25","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0006-291X(03)00407-8","article-title":"Ethanol feeding induces insulin resistance with enhanced PI 3-kinase activation","volume":"303","author":"Onishi","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10.1016\/j.cld.2025.09.003_bib26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/acer.12075","article-title":"Temporal effects of ethanol consumption on energy homeostasis, hepatic steatosis, and insulin sensitivity in mice","volume":"37","author":"Carr","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"10.1016\/j.cld.2025.09.003_bib27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S2213-8587(19)30410-3","article-title":"Alcohol and illicit drug use in people with diabetes","volume":"8","author":"Pastor","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 3","key":"10.1016\/j.cld.2025.09.003_bib28","doi-asserted-by":"crossref","first-page":"S371","DOI":"10.33549\/physiolres.933178","article-title":"Moderate alcohol consumption and triglyceridemia","volume":"64","author":"Kov\u00e1\u0159","year":"2015","journal-title":"Physiol Res"},{"issue":"4","key":"10.1016\/j.cld.2025.09.003_bib29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MOL.0b013e3283606845","article-title":"Alcohol and plasma triglycerides","volume":"24","author":"Klop","year":"2013","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"10.1016\/j.cld.2025.09.003_bib30","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","article-title":"Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease","volume":"82","author":"Arab","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.09.003_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2025.01.003","article-title":"Association of alcohol and incremental cardiometabolic risk factors with liver disease: a national cross-sectional study","author":"Lee","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.09.003_bib32","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1002\/hep.29055","article-title":"Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review","volume":"65","author":"Ajmera","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2025.09.003_bib33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2021.09.030","article-title":"Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus","volume":"76","author":"Mallet","year":"2022","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2025.09.003_bib34","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1111\/liv.15004","article-title":"Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease","volume":"41","author":"M\u00e4nnist\u00f6","year":"2021","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.cld.2025.09.003_bib35","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","article-title":"Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease","volume":"81","author":"Marti-Aguado","year":"2024","journal-title":"J Hepatol"},{"issue":"10464","key":"10.1016\/j.cld.2025.09.003_bib70","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2025.09.003_bib36","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.neubiorev.2021.02.006","article-title":"Consistency between self-reported alcohol consumption and biological markers among patients with alcohol use disorder - a systematic review","volume":"124","author":"Gr\u00fcner Nielsen","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"10.1016\/j.cld.2025.09.003_bib71","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2468-1253(24)00427-8","article-title":"Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD","volume":"10","author":"Krag","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2025.09.003_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.40202","article-title":"Trends in public stigma of mental illness in the US, 1996-2018","volume":"4","author":"Pescosolido","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.cld.2025.09.003_bib38","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000617","article-title":"Reluctance to accept alcohol treatment by alcoholic liver disease transplant patients: a qualitative study","volume":"2","author":"Heyes","year":"2016","journal-title":"Transplant Direct"},{"key":"10.1016\/j.cld.2025.09.003_bib39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13011-015-0028-z","article-title":"Alcohol use disorder severity and reported reasons not to seek treatment: a cross-sectional study in European primary care practices","volume":"10","author":"Probst","year":"2015","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"2","key":"10.1016\/j.cld.2025.09.003_bib40","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2022.04.026","article-title":"The stigma of alcohol-related liver disease and its impact on healthcare","volume":"77","author":"Schomerus","year":"2022","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.09.003_bib41","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/MCG.0000000000001852","article-title":"Role of biomarkers to assess the use of alcohol","volume":"57","author":"Shetty","year":"2023","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2025.09.003_bib42","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption--II","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.cld.2025.09.003_bib43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0895-4356(03)00254-3","article-title":"The value of the CAGE in screening for alcohol abuse and alcohol dependence in general clinical populations: a diagnostic meta-analysis","volume":"57","author":"Aertgeerts","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.cld.2025.09.003_bib44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0376-8716(96)01263-X","article-title":"The reliability of the alcohol timeline followback when administered by telephone and by computer","volume":"42","author":"Sobell","year":"1996","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.cld.2025.09.003_bib45","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/alcalc\/agh064","article-title":"Blood alcohol is the best indicator of hazardous alcohol drinking in young adults and working-age patients with trauma","volume":"39","author":"Savola","year":"2004","journal-title":"Alcohol Alcohol"},{"issue":"6","key":"10.1016\/j.cld.2025.09.003_bib46","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/apt.18506","article-title":"Head-to-Head comparison between phosphatidylethanol versus indirect alcohol biomarkers for diagnosis of MetALD versus MASLD: a prospective study","volume":"61","author":"Tavaglione","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2025.09.003_bib47","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1530-0277.2012.01855.x","article-title":"Sensitivity and specificity of urinary ethyl glucuronide and ethyl sulfate in liver disease patients","volume":"37","author":"Stewart","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.cld.2025.09.003_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.07.019","article-title":"Phosphatidylethanol in steatotic liver disease","author":"Torp","year":"2025","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2025.09.003_bib48","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.33182","article-title":"Phosphatidylethanol vs transdermal alcohol monitoring for detecting alcohol consumption among adults","volume":"6","author":"Hahn","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.cld.2025.09.003_bib49","article-title":"Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake","volume":"7","author":"Hansen","year":"2025","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.cld.2025.09.003_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101162","article-title":"Alcohol-associated liver disease: epidemiology and management","volume":"29","author":"Hern\u00e1ndez-\u00c9vole","year":"2024","journal-title":"Ann Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2025.09.003_bib51","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/17474124.2024.2385487","article-title":"Integrating behavioral interventions into a holistic approach to metabolic dysfunction-associated steatotic liver disease","volume":"18","author":"Righetti","year":"2024","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.09.003_bib52","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/nbu.12707","article-title":"Mediterranean diet for the management of metabolic dysfunction-associated steatotic liver disease in non-Mediterranean, Western countries: what's known and what's needed?","volume":"49","author":"Sualeheen","year":"2024","journal-title":"Nutr Bull"},{"issue":"7","key":"10.1016\/j.cld.2025.09.003_bib53","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1056\/NEJMct0801733","article-title":"Naltrexone for the management of alcohol dependence","volume":"359","author":"Anton","year":"2008","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.cld.2025.09.003_bib54","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis","volume":"330","author":"McPheeters","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.cld.2025.09.003_bib55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcp.12070","article-title":"The clinical pharmacology of acamprosate","volume":"77","author":"Kalk","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.cld.2025.09.003_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.cld.2025.09.003_bib57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00213-024-06637-2","article-title":"Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys","volume":"242","author":"Fink-Jensen","year":"2025","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"10.1016\/j.cld.2025.09.003_bib58","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.cld.2025.09.003_bib59","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"11\u201312","key":"10.1016\/j.cld.2025.09.003_bib60","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4\u2009mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2025.09.003_bib61","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2025.09.003_bib62","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2025.09.003_bib63","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2025.09.003_bib64","doi-asserted-by":"crossref","unstructured":"Noureddin M, Kowdley KV, Clawson A, et al. Once-monthly efimosfermin alfa (BOS-580) in metabolic dysfunction-associated steatohepatitis with F2\/F3 fibrosis: results from a 24 week, randomized, double-blind, placebo-controlled, phase 2 trial. AASLD abstract 5017. Presented at: The Liver Meeting; November 15-19, 2024; San Diego (CA).","DOI":"10.1016\/S0016-5085(25)04659-1"},{"issue":"24","key":"10.1016\/j.cld.2025.09.003_bib73","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2025.09.003_bib65","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cmet.2021.12.024","article-title":"FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit","volume":"34","author":"Flippo","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.cld.2025.09.003_bib66","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mce.2018.10.014","article-title":"Role of HSD17B13 in the liver physiology and pathophysiology","volume":"489","author":"Su","year":"2019","journal-title":"Mol Cell Endocrinol"},{"issue":"12","key":"10.1016\/j.cld.2025.09.003_bib67","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.cld.2025.09.003_bib68","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.cgh.2022.11.002","article-title":"The protection conferred by HSD17B13 rs72613567 on hepatic fibrosis is likely mediated by lowering ballooning and portal inflammation","volume":"21","author":"Vilar-Gomez","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2025.09.003_bib69","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1113\/EP092535","article-title":"Hydroxysteroid 17\u03b2-dehydrogenase 13 (Hsd17b13) knockdown attenuates liver steatosis in high-fat diet obese mice","volume":"110","author":"Mahmood","year":"2025","journal-title":"Exp Physiol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:02:49Z","timestamp":1763762569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125000844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1089326125000844"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.09.003","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic and Alcohol-Associated","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}